Replies to post #213724 on Biotech Values

[poorgradstudent]

MYOK:

I think their data to date looks reasonable. As I mentioned earlier, I like their approach of reducing force production.

The targeted hypertrophic cardiomyopathy angle did turn out to be bunk, since they don't seem to be focusing on a mutation-driven strategy. I actually think that's a good thing.